Parkinson's Disease/Movement Disorders News

SAN DIEGO – One compound from Annovis Bio is showing success in phase 2 clinical trials for both Alzheimer’s disease and Parkinsons’ disease, a company executive said at the Alzheimer’s Association International Conference.

The FDA has approved Relyvrio, an oral, fixed-dose combination therapy for the treatment of adults with ALS, Amylyx Pharmaceuticals Inc. announced in a press release.

LAS VEGAS — When evaluating the best choice for on-demand therapies for off time in Parkinson’s disease, physicians should consider severity of side effects, time to efficacy and patient preference, a presenter stated at BRAINWeek 2022.

The National Center of Excellence in Research on Parkinson’s Disease in Luxembourg has launched an online survey in collaboration with regional research centers to improve risk prediction for neurodegenerative diseases.

Acupuncture was shown to be an effective treatment for anxiety in patients with Parkinson’s disease, researchers reported in JAMA Network Open.

Although ankylosing spondylitis correlates with higher rates of Alzheimer’s disease, patients who receive TNF inhibitors are less likely to develop the neurologic disorder, according to data published in Pharmacological Research.

CuraSen Therapeutics Inc. announced it has begun dosing patients in a phase 2a clinical trial with CST-2032, an oral therapeutic for treatment of mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease.

Results of a recently released poll revealed that roughly 60% of patients with Parkinson’s disease do not believe their symptoms are manageable and cannot be improved beyond their current state.

LAS VEGAS — Lesser-known cannabinoids are showing potential for treating neurological disease, inflammation, pain, cancer and infection, according to dermatologist Jeanette Jacknin, MD.

Amneal Pharmaceuticals Inc. announced it has submitted a new drug application to the FDA for IPX203, an oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson’s disease.